The Role of Rituximab in Lymphomas
Over the last years the treatment of non-Hodgkin's lymphoma underwent a great advance in relation to the diagnosis, classification, high-dose chemotherapy, and hematopoietic stem cell transplantation. Simultaneously with this, there was the development of new drugs and support therapy which enabled an improvement in the evolution and survival of the patients. The use of monoclonal antibodies against cancer cells is an old idea and in this report the results of the role of the anti-CD20-Rituximab in lymphomas is discussed.
Saved in:
| Main Author: | |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
2002
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842002000300004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|